{"id":"FA4479B9-FFED-4BD0-9294-CA32EEAC4047","title":"Pentraxins and amyloidosis: from molecular mechanisms to medicines","abstractText":"We have invented a platform technology for creation of drugs to target any blood protein that causes disease and are using it to develop new medicines.&nbsp; Our most advanced drug compound targets serum amyloid P component (SAP) and is undergoing clinical testing in amyloidosis, Alzheimerâ€™s disease and osteoarthritis.&nbsp; It may also be useful in type 2, maturity onset, diabetes.&nbsp; Other drugs are being designed to treat and prevent hitherto untreatable lethal forms of inherited and acquired amyloidosis.&nbsp; Our drug which targets C?reactive protein (CRP) is beneficial in rat models of heart attack and stroke, and will be developed for clinical trials.\n&nbsp;\nThe MRC has funded, continuously since 1979, our research on CRP and SAP, which are related human blood proteins, and our work on amyloidosis, a usually fatal disease. &nbsp;We study the individual proteins, their interactions with each other and with cells, and animal models of human disease, and we also perform clinical testing in patients.\n&nbsp;\nWe have introduced new methods of diagnosis and treatment that improve quality and duration of life for most patients who attend the world leading NHS National Amyloidosis Centre in our Department.&nbsp; We will continue to refine and develop these methods.","grantUrl":"http://gtr.rcuk.ac.uk/projects?ref=G7900510","grantId":"G7900510","fundValue":"9935460","fundStart":"1979-10-01","fundEnd":"2010-03-31","funder":"MRC","impactText":"","person":"Mark Brian Pepys","coPersons":["Philip Nigel Hawkins"],"organisation":"University College London","findingsText":"","dataset":"gtr"}